486 related articles for article (PubMed ID: 25676488)
1. The role of nonrandomized trials in the evaluation of oncology drugs.
Simon R; Blumenthal GM; Rothenberg ML; Sommer J; Roberts SA; Armstrong DK; LaVange LM; Pazdur R
Clin Pharmacol Ther; 2015 May; 97(5):502-7. PubMed ID: 25676488
[TBL] [Abstract][Full Text] [Related]
2. Pathology is a necessary and informative tool in oncology clinical trials.
Nagtegaal ID; West NP; van Krieken JH; Quirke P
J Pathol; 2014 Jan; 232(2):185-9. PubMed ID: 24037805
[TBL] [Abstract][Full Text] [Related]
3. Oncology trial design: More accurately and efficiently advancing the field.
Hohl RJ
Clin Pharmacol Ther; 2015 May; 97(5):430-2. PubMed ID: 25684240
[No Abstract] [Full Text] [Related]
4. N-of-1 trials in oncology.
Collette L; Tombal B
Lancet Oncol; 2015 Aug; 16(8):885-6. PubMed ID: 26248830
[No Abstract] [Full Text] [Related]
5. Improving evidence developed from population-level experience with targeted agents.
McClellan MB; Daniel GW; Dickson D; Perlmutter J; Berger DP; Miller V; Nussbaum S; Malin J; Romine MH; Schilsky RL
Clin Pharmacol Ther; 2015 May; 97(5):478-87. PubMed ID: 25676878
[TBL] [Abstract][Full Text] [Related]
6. Effect of Crossover in Oncology Clinical Trials on Evidence Levels in Early Benefit Assessment in Germany.
Isbary G; Staab TR; Amelung VE; Dintsios CM; Iking-Konert C; Nesurini SM; Walter M; Ruof J
Value Health; 2018 Jun; 21(6):698-706. PubMed ID: 29909875
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer.
Kesselheim AS; Myers JA; Avorn J
JAMA; 2011 Jun; 305(22):2320-6. PubMed ID: 21642684
[TBL] [Abstract][Full Text] [Related]
8. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval.
Sobrero A; Bruzzi P
J Clin Oncol; 2009 Dec; 27(35):5868-73. PubMed ID: 19826122
[No Abstract] [Full Text] [Related]
9. How good is "evidence" from clinical studies of drug effects and why might such evidence fail in the prediction of the clinical utility of drugs?
Naci H; Ioannidis JP
Annu Rev Pharmacol Toxicol; 2015; 55():169-89. PubMed ID: 25149917
[TBL] [Abstract][Full Text] [Related]
10. An FDA oncology view of juvenile animal studies in support of initial pediatric trials for anticancer drugs.
Leighton JK; Saber H; Reaman G; Pazdur R
Regul Toxicol Pharmacol; 2016 Aug; 79():142-143. PubMed ID: 26952647
[No Abstract] [Full Text] [Related]
11. Choice of control group in randomised trials of cancer medicine: are we testing trivialities?
Tao D; Prasad V
Lancet Oncol; 2018 Sep; 19(9):1150-1152. PubMed ID: 30191836
[No Abstract] [Full Text] [Related]
12. Reflections on ethical concerns arising from the incorporation of results of randomized trials of antineoplastic therapy into routine clinical practice.
Markman M
Cancer Invest; 2005; 23(8):735-40. PubMed ID: 16377592
[TBL] [Abstract][Full Text] [Related]
13. Expansion Cohorts in First-in-Human Solid Tumor Oncology Trials.
Theoret MR; Pai-Scherf LH; Chuk MK; Prowell TM; Balasubramaniam S; Kim T; Kim G; Kluetz PG; Keegan P; Pazdur R
Clin Cancer Res; 2015 Oct; 21(20):4545-51. PubMed ID: 26473190
[TBL] [Abstract][Full Text] [Related]
14. Evaluating Antiretroviral Therapy Initiation in HIV-Associated Malignancy: Is There Enough Evidence to Inform Clinical Guidelines?
Oseso LN; Chiao EY; Bender Ignacio RA
J Natl Compr Canc Netw; 2018 Aug; 16(8):927-932. PubMed ID: 30099368
[No Abstract] [Full Text] [Related]
15. [Clinical practice guidelines for the adverse events in medical oncology].
Isobe T; Hayashi M; Tsubata Y
Nihon Rinsho; 2015 Feb; 73 Suppl 2():45-50. PubMed ID: 25831722
[No Abstract] [Full Text] [Related]
16. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group.
Stone AM; Bushnell W; Denne J; Sargent DJ; Amit O; Chen C; Bailey-Iacona R; Helterbrand J; Williams G;
Eur J Cancer; 2011 Aug; 47(12):1763-71. PubMed ID: 21435858
[TBL] [Abstract][Full Text] [Related]
17. Personalized Medicine: Genomics Trials in Oncology.
Hayes DF; Schott AF
Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
[TBL] [Abstract][Full Text] [Related]
18. The ethics of phase 0 oncology trials.
Abdoler E; Taylor H; Wendler D
Clin Cancer Res; 2008 Jun; 14(12):3692-7. PubMed ID: 18559585
[TBL] [Abstract][Full Text] [Related]
19. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
[TBL] [Abstract][Full Text] [Related]
20. Progression-free survival as an end-point in solid tumours--perspectives from clinical trials and clinical practice.
Robinson AG; Booth CM; Eisenhauer EA
Eur J Cancer; 2014 Sep; 50(13):2303-8. PubMed ID: 24974171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
